Provided by Tiger Fintech (Singapore) Pte. Ltd.

KEYMED BIO-B

59.400
-1.400-2.30%
Volume:1.71M
Turnover:102.91M
Market Cap:17.76B
PE:-27.69
High:62.000
Open:61.650
Low:59.300
Close:60.800
52wk High:80.000
52wk Low:27.050
Shares:299.00M
HK Float Shares:299.00M
Volume Ratio:1.48
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-2.145
ROE:-8.82%
ROA:-5.44%
PB:5.10
PE(LYR):-27.69
PS:18.67

Loading ...

Hong Kong Stocks Movement | Pharmaceutical Stocks Continue Multi-Day Decline Amid Short-Term External Environment Changes, Institutions Remain Optimistic About Long-Term Industry Development Trends

Stock News
·
Oct 14

Hong Kong Stock Movement | KEYMED BIO-B (02162) Surges Over 5% Intraday as First Dual-Antibody Drug CM336 Initiates Phase III Study

Stock News
·
Sep 22

Is There Still Potential in Keymed Biosciences After Shares Double in 2025?

Simply Wall St.
·
Sep 14

Hong Kong Stocks Alert | KEYMED BIO-B (02162) Surges Over 10% in Morning Session on Strong H1 Subcilizumab Commercial Performance and Robust Competitive Position in Atopic Dermatitis Market

Stock News
·
Sep 05

Bank of Communications International Raises KEYMED BIO-B Target Price to HK$78 as Core Products Accelerate Market Penetration in H1

Stock News
·
Aug 29

KeyMed Biosciences (02162.HK) Reports Strong Interim 2025 Results With Accelerated Commercialization and Robust R&D Momentum

THOMSON REUTERS
·
Aug 27

HK Movers | Biotech Stocks Decline, Clover Biopharmaceuticals Drops Over 14%

Tiger Newspress
·
Aug 27

Stock Track | KEYMED BIO-B Soars 5.09% as CICC Raises Target Price by 54.5% to HK$85.00

Stock Track
·
Aug 27

CICC Maintains Outperform Rating on KEYMED BIO-B (02162), Raises Target Price to HK$85.00

Stock News
·
Aug 27

Keymed Biosciences Narrows Loss in H1; CFO Steps Down

MT Newswires Live
·
Aug 26

KEYMED BIO-B (02162) Reports Interim Results with Shareholder Loss of RMB 78.84 Million, Narrowing by 76.59% Year-on-Year

Stock News
·
Aug 26

KeyMed Biosciences H1 Revenue RMB 169 Million

THOMSON REUTERS
·
Aug 26

Keymed Biosciences Inc. Conducted Annual General Meeting

Reuters
·
Jun 26

Keymed Biosciences Raises HK$853.8 Million from Top-Up Placement

MT Newswires Live
·
Jun 19

Keymed Biosciences Inc. Completes Placing of Existing Shares and Top-Up Subscription of New Shares Under General Mandate

Reuters
·
Jun 19

Keymed Biosciences Inc. Announces Promising Clinical Trial Results for CM336 in Treating Refractory Autoimmune Hemolytic Anemia

Reuters
·
Jun 13

BRIEF-Keymed Biosciences Places 21.6 Mln Shares At HK$45.48 Per Share

Reuters
·
Jun 11

Keymed Biosciences Inc. Announces Placing of Existing Shares and Top-Up Subscription of New Shares Under General Mandate, Along with Sale of Shares by Top-Up Vendor

Reuters
·
Jun 11